MedTrace Logo

Immune Response Under Immunotherapy in Metastatic NSCLC: Sputum, Blood Samples and Microbioata Study

NCT04804137 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2024-01-17

No results posted yet for this study

Summary

Prospective pathophysiological exploratory monocentric study, focusing on adult patients with non-small cell lung cancer (NSCLC) : non-squamous type without oncogenic addiction, metastatic, treated with immune checkpoint inhibitors alone or in combination with chemotherapy in front line at the CHRU de Tours, France.

Conditions

  • Non-squamous Lung Cancer
  • Metastatic Lung Cancer

Interventions

OTHER

Blood

Blood samples are taken at each visit to the day hospital for a programmed injection of immunotherapy.

OTHER

sputum

induced by saline aerosol sputum during each visit to the day hospital for a programmed injection of immunotherapy.

OTHER

saliva

spontaneous saliva during each visit to the day hospital for a programmed injection of immunotherapy.

OTHER

stool

Stool analyses will be carried out on a sample taken by the patient at home and brought back at the time of a day hospital.

Sponsors & Collaborators

  • Cedars-Sinai Medical Center

    collaborator OTHER

  • University Hospital, Tours

    lead OTHER

Principal Investigators

  • Marion FERREIRA · University Hospital, Tours

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-03
Primary Completion
2022-09-26
Completion
2023-07-31

Countries

  • United States
  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04804137 on ClinicalTrials.gov